Biarylmethyl heterocycles

US12037324B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12037324-B2
Application numberUS-202217861809-A
CountryUS
Kind codeB2
Filing dateJul 11, 2022
Priority dateJun 29, 2016
Publication dateJul 16, 2024
Grant dateJul 16, 2024

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound of formula (I), or salt thereof: wherein ring A is W is N, or CR 16 W′, at each occurrence, is independently selected from N, O, S and CR 16 where at least one W′ is not CR 16 , and at most only one W′ is selected as O or S; R 1 and R 2 are independently selected from H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 alkoxyalkyl, and C 3 -C 6 cycloalkyl; alternatively, R 1 and R 2 , together with the atom to which they are attached, join together to form a C 3 -C 6 cycloalkyl, or a 4 to 6 membered heterocycle having 1-2 heteroatoms, the cycloalkyl or heterocycle is substituted with 0-4 F and 0-1 OH; R 16 , at each occurrence, is independently selected from H, F, Cl, Br, I, CN, OH, N(R a ) 2 , C 1 -C 3 -alkyl, C 1 -C 3 -haloalkyl, C 1 -C 3 -alkoxy, C 1 -C 4 -hydroxyalkyl, C 1 -C 3 -haloalkoxy, C 3 -C 6 -cycloalkyl, and C 3 -C 6 -halocycloalkyl R a is, at each occurrence, independently selected from H, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 1 -C 4 -hydroxyalkyl, and C 3 -C 6 -cycloalkyl; or two R a , along with the nitrogen atom to which they are attached, join to form a 5 to 6 membered heterocycle containing 0-2 additional heteroatoms selected from N, O and S; Y is 5-tetrazolyl, SO 3 H, PO 2 H 2 , PO 3 H 2 , COOR, R, at each occurrence, is independently selected from H, C 1 -C 6 alkyl, C 1 -C 6 -haloalkyl, C 1 -C 6 -hydroxyalkyl, C 3 -C 7 cycloalkyl, C 6 aryl-C 1 -C 6 alkyl heterocycle-C 1 -C 6 alkyl, wherein said heterocycle is a 4-10 membered group having 1-3 heteroatoms selected from N, O, or S, said aryl and heterocycle are each substituted with 0-3 groups chosen from C 1 -C 3 alkyl, halo, OH, or C 1 -C 3 fluoroalkyl; R 8 at each occurrence, is independently selected from H, C 1 -C 6 alkyl, C 1 -C 6 -haloalkyl, C 1 -C 6 -hydroxyalkyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, C 6-10 aryl, C 6-10 -aryl-C 1 -C 6 -alkyl, heteroaryl, heteroaryl-C 1 -C 6 -alkyl, heterocyclyl, heterocycle-C 1 -C 6 -alkyl, wherein the heteroaryl and heterocycle are each a 4-10 membered group having 1-3 heteroatoms selected from N, O, or S; Z, at each occurrence, is independently selected from a bond, O, S, N(R z ), C(R z ) 2 , C═O, C(═O)N(R z ), N(R z )C(═O), C(R z ) 2 C(R z ) 2 , OC(R z ) 2 , SC(R z ) 2 , N(R z )C(R z ) 2 , C(R z ) 2 O, C(R z ) 2 S, C(R z ) 2 N(R z ); R z is at each occurrence independently selected from H, C 1 -C 4 -alkyl, C 1 -C 4 -hydroxyalkyl, C 1 -C 4 -haloalkyl, C 3 -C 6 -cycloalkyl or, alternatively, two R z groups either on the same atom or on adjacent atoms can join to form a C 3 -C 6 -cycloalkyl or a 4 to 7 membered heterocycle containing 1-2 heteroatoms selected from N, O and S; G is selected from a 4 to 11 membered heterocycle having 1-4 atoms selected from N, O, and S, a C 3 -C8-cycloalkyl, C 6 -C 10 -aryl or a 5 to 10 membered heteroaryl having 1-4 atoms selected from N, O, and S; wherein the heterocycle, cycloalkyl, aryl and heteroaryl are substituted with 0-3 substituents independently selected from the group consisting of ═O, F, Cl, Br, I, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, C 1 -C 6 -haloalkyl, C 1 -C 6 -hydroxyalkyl, OH, OR x , SR x , N(R x ) 2 , CO(R x ), CON(R x ) 2 , CO 2 R x , N(R x )CO 2 (R x ), N(R x )CO(R x ), N(R x )CON(R x ) 2 , S(O) 2 (R x ), S(O) 2 N(R x ) 2 , or N(R x )S(O) 2 (R x ); R x is H, C 1-6 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, phenyl, CH 2 -phenyl; ring B is Group C is R 5 is C 1-6 alkyl, C 1-6 haloalkyl C 1-6 alkoxyalkyl, C 3-6 -cycloalkylC 0-4 -alkyl which may be substituted with 1-3 halogens or a C 1-3 -alkoxy group; R 6 is H, F, Cl, Br, CF 3 , CN, N(R z ) 2 , CON(R z ) 2 , C 1-4 alkyl, C 1-4 haloalkyl C 1-4 alkoxyalkyl, C 1-4 hydroxyalkyl, C 3-6 -cycloalkyl, C 3-6 -halocycloalkyl, C 3-6 -alkoxycycloalkyl, or C 3-6 -hydroxycycloalkyl; R 9 is COOR, CON(R z ) 2 ; and r is 0 to 3; provided that the compounds of Formula (I) are not 2. A compound of claim 1 , or salt thereof, wherein R 5 is C 1-6 alkyl or C 3-6 cycloalkyl; R 9 is CO 2 H, CO 2 -C 1-6 -alkyl; and R 6 is hydrogen, or C 1-4 alkyl. 3. A compound of claim 1 , or salt thereof, wherein G is selected from a 5 to 10 membered heterocycle having 1-3 atoms selected from N, O, and S, phenyl or a C 6 -C 10 -heteroaryl having 1-3 atoms selected from N, O, and S; wherein the heterocycle, phenyl and heteroaryl are substituted with 0-3 substituents independently selected from the group consisting of ═O, Cl, Br, I, F, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, C 1 -C 6 -haloalkyl, C 1 -C 6 -alkylthio, C 1 -C 6 -hydroxyalkyl, OH, OR x , N(R x ) 2 , CO(R x ), CON(R x ) 2 , CO 2 R x , N(R x )CO 2 (R x ), N(R x )CO(R x ), N(R x )CON(R x ) 2 , S(O) 2 (R x ), S(O) 2 N(R x ) 2 , or N(R x )S(O) 2 R x ; R x is H, C 1-6 alkyl, CF 3 , phenyl, CH 2 -phenyl. 4. A compound of claim 1 , or salt thereof, wherein Ring B is any of which are optionally substituted with 0-2 F. 5. A compound of claim 1 , or salt thereof, wherein Ring B is any of which are optionally substituted with 0-2 F, Y is COOH, COOMe, COOEt, 5-tetrazolyl, SO 3 H, 6. A compound of claim 1 , or salt thereof, wherein wherein Y is COOH, 5-tetrazolyl, SO 3 H, R=C 1-6 alkyl, C 6-10 -aryl-C 1 -C 6 -alkyl, or (CH 2

Assignees

Inventors

Classifications

  • with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical · CPC title

  • having two double bonds between ring members or between ring members and non-ring members · CPC title

  • not condensed and containing further heterocyclic rings · CPC title

  • containing further heterocyclic rings · CPC title

  • Non-condensed quinolines and containing further heterocyclic rings · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12037324B2 cover?
The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.
Who is the assignee on this patent?
Univ Montreal, Bristol Myers Squibb Co
What technology area does this patent fall under?
Primary CPC classification A61K31/41. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).